Be­yond BR­CA: As­traZeneca rounds out ES­MO with a case for ex­pand­ed bio­mark­er in prostate can­cer

BARCELONA — When it comes to se­lect­ing pa­tients for PARP in­hibitors, mu­ta­tions in the BR­CA1 and BR­CA2 genes have been the go-to bio­mark­er, the surest way of find­ing those most like­ly to ben­e­fit from the ther­a­py. But As­traZeneca and Mer­ck are mak­ing some head­way in carv­ing out a new niche for it­self in prostate can­cer.

Greg Rossi
Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.